One of the main challenges in targeting BUBR1 is its dual role in cancer. While loss of BUBR1 function can promote cancer, its overexpression can also be detrimental. Therefore, therapeutic strategies need to be carefully tailored to the specific context of BUBR1 expression in different cancers. Moreover, potential side effects due to the disruption of normal mitotic processes in healthy cells must be considered.
